Literature DB >> 18091430

Osteopenia: a common aspect of Fabry disease. Predictors of bone mineral density.

Henriette Mersebach1, Jan-Ove Johansson, Ase Krogh Rasmussen, Bengt-Ake Bengtsson, Kirsten Rosenberg, Lis Hasholt, Sven Asger Sørensen, Søren Schwartz Sørensen, Ulla Feldt-Rasmussen.   

Abstract

PURPOSE: We investigated the bone mineral status in patients with untreated Fabry disease (FD).
METHODS: Descriptive, cross-sectional study in 53 patients with FD investigating bone mineral density (BMD)/content (dual energy x-ray absorptiometry scan), bone metabolism (parathyroid hormone, osteocalcin, and insulin-like growth factor I), and renal function (ethylene diamine tetraacetic acid clearance).
RESULTS: Mean BMD z score at the lumbar spine and femoral neck were -0.05 +/- 1.46 SD and -0.37 +/- 1.02 SD, respectively. Approximately 50% had osteopenia in the hip or lumbar spine and additionally four had osteoporosis. Multivariate analysis including body weight, impaired renal function, and genotype overall explained 48% of the variance in lumbar spine BMD (P < 0.001), whereas body weight, impaired renal function, and menopausal status in the female population accounted for more than 50% of the variation in BMD of both the lumbar spine and femoral neck (both P < 0.001). Twenty percent of patients had hyperparathyroidism. Although the level of parathyroid hormone was significantly associated with impaired renal function, osteocalcin levels were significantly higher in patients with lumbar spine osteopenia or osteoporosis than in those with normal BMD.
CONCLUSIONS: Osteopenia was present in approximately 50% of patients with untreated FD. Whether BMD and bone metabolism will improve after enzyme replacement therapy remains to be established.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18091430     DOI: 10.1097/gim.0b013e31815cb197

Source DB:  PubMed          Journal:  Genet Med        ISSN: 1098-3600            Impact factor:   8.822


  16 in total

1.  Skeletal manifestations in pediatric and adult patients with Niemann Pick disease type B.

Authors:  Melissa Wasserstein; James Godbold; Margaret M McGovern
Journal:  J Inherit Metab Dis       Date:  2012-06-21       Impact factor: 4.982

2.  Enzyme therapy in Fabry disease: severe adverse events associated with anti-agalsidase cross-reactive IgG antibodies.

Authors:  Chloe Tesmoingt; Olivier Lidove; Axele Reberga; Marguerite Thetis; Chloe Ackaert; Pascale Nicaise; Philippe Arnaud; Thomas Papo
Journal:  Br J Clin Pharmacol       Date:  2009-11       Impact factor: 4.335

3.  Antiepileptic medications increase osteoporosis risk in male fabry patients: bone mineral density in an Australian cohort.

Authors:  Andrew Talbot; Joanna R Ghali; Kathy Nicholls
Journal:  JIMD Rep       Date:  2014-07-26

4.  Awareness of Fabry disease among rheumatologists--current status and perspectives.

Authors:  Rolando Cimaz; Severine Guillaume; Max J Hilz; Gerd Horneff; Bernhard Manger; J Carter Thorne; Anette Torvin Møller; Nico M Wulffraat; Johannes Roth
Journal:  Clin Rheumatol       Date:  2011-04       Impact factor: 2.980

5.  The Influence of Patient-Reported Joint Manifestations on Quality of Life in Fabry Patients.

Authors:  Alexandra Ivleva; Ekaterina Weith; Atul Mehta; Derralynn A Hughes
Journal:  JIMD Rep       Date:  2018-01-30

Review 6.  Progress in the understanding and treatment of Fabry disease.

Authors:  James J Miller; Adam J Kanack; Nancy M Dahms
Journal:  Biochim Biophys Acta Gen Subj       Date:  2019-09-14       Impact factor: 3.770

Review 7.  Fabry disease.

Authors:  Dominique P Germain
Journal:  Orphanet J Rare Dis       Date:  2010-11-22       Impact factor: 4.123

8.  Successful salvage therapy with Daptomycin for osteomyelitis caused by methicillin-resistant Staphylococcus aureus in a renal transplant recipient with Fabry-Anderson disease.

Authors:  Ennio Polilli; Tamara Ursini; Elena Mazzotta; Federica Sozio; Vincenzo Savini; Domenico D'Antonio; Michelino Barbato; Augusta Consorte; Giustino Parruti
Journal:  Ann Clin Microbiol Antimicrob       Date:  2012-03-11       Impact factor: 3.944

9.  Positron Emission Tomography and Magnetic Resonance Imaging of the Brain in Fabry Disease: A Nationwide, Long-Time, Prospective Follow-Up.

Authors:  Kirsten Korsholm; Ulla Feldt-Rasmussen; Henrik Granqvist; Liselotte Højgaard; Birgit Bollinger; Aase K Rasmussen; Ian Law
Journal:  PLoS One       Date:  2015-12-02       Impact factor: 3.240

10.  Assessment of bone mineral density by dual energy x-ray absorptiometry in patients with mucopolysaccharidoses.

Authors:  Hsiang-Yu Lin; Shou-Chuan Shih; Chih-Kuang Chuang; Ming-Ren Chen; Dau-Ming Niu; Shuan-Pei Lin
Journal:  Orphanet J Rare Dis       Date:  2013-05-11       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.